Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Marinus Pharmaceuticals initiated with an Outperform at Cowen » 06:18
07/01/20
07/01
06:18
07/01/20
06:18
MRNS

Marinus Pharmaceuticals

$2.53 /

+0.01 (+0.40%)

Cowen analyst Joseph…

Cowen analyst Joseph Thome initiated coverage of Marinus Pharmaceuticals with an Outperform rating.

ShowHide Related Items >><<
MRNS Marinus Pharmaceuticals
$2.53 /

+0.01 (+0.40%)

MRNS Marinus Pharmaceuticals
$2.53 /

+0.01 (+0.40%)

07/01/20 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $9 from $6 at H.C. Wainwright
04/09/20 Craig-Hallum
Marinus Pharmaceuticals initiated with a Buy at Craig-Hallum
01/10/20 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $6 from $5 at H.C. Wainwright
12/20/19
Fly Intel: Top five analyst initiations
MRNS Marinus Pharmaceuticals
$2.53 /

+0.01 (+0.40%)

  • 29
    May
  • 11
    Dec
Recommendations
Marinus Pharmaceuticals price target raised to $9 from $6 at H.C. Wainwright » 06:15
07/01/20
07/01
06:15
07/01/20
06:15
MRNS

Marinus Pharmaceuticals

$2.53 /

+0.01 (+0.40%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Douglas Tsao raised the firm's price target on Marinus Pharmaceuticals to $9 from $6 and reiterates a Buy rating on the shares. The company yesterday hosted a virtual R&D day providing an update on ganaxolone's clinical trials while touching on potential development and commercial strategy for the refractory status epilepticus and the orphan epilepsy indications, Tsao tells investors in a research note.

ShowHide Related Items >><<
MRNS Marinus Pharmaceuticals
$2.53 /

+0.01 (+0.40%)

MRNS Marinus Pharmaceuticals
$2.53 /

+0.01 (+0.40%)

04/09/20 Craig-Hallum
Marinus Pharmaceuticals initiated with a Buy at Craig-Hallum
01/10/20 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $6 from $5 at H.C. Wainwright
12/20/19
Fly Intel: Top five analyst initiations
12/19/19 Oppenheimer
Marinus Pharmaceuticals initiated with an Outperform at Oppenheimer
MRNS Marinus Pharmaceuticals
$2.53 /

+0.01 (+0.40%)

  • 29
    May
  • 11
    Dec
Tuesday
Conference/Events
Marinus Pharmaceuticals to hold a pipeline update webinar » 07:25
06/30/20
06/30
07:25
06/30/20
07:25
MRNS

Marinus Pharmaceuticals

$2.52 /

-0.08 (-3.08%)

Pipeline Update Webinar…

Pipeline Update Webinar to provide a clinical update and commercial overview on the Company's pipeline programs in Status Epilepticus, CDKL5 Deficiency Disorder and Tuberous Sclerosis Complex will be held on June 30 at 8 am. Webcast Link

ShowHide Related Items >><<
MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

04/09/20 Craig-Hallum
Marinus Pharmaceuticals initiated with a Buy at Craig-Hallum
01/10/20 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $6 from $5 at H.C. Wainwright
12/20/19
Fly Intel: Top five analyst initiations
12/19/19 Oppenheimer
Marinus Pharmaceuticals initiated with an Outperform at Oppenheimer
MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

  • 29
    May
  • 11
    Dec
Hot Stocks
Marinus increases enrollment in PCDH19 PoC trial to 25-30 from 15-20 » 07:15
06/30/20
06/30
07:15
06/30/20
07:15
MRNS

Marinus Pharmaceuticals

$2.52 /

-0.08 (-3.08%)

Marinus remains on-track…

Marinus remains on-track to enroll 25-30 patients in the ongoing Phase 2 Violet Study evaluating allopregnanolone sulfate as a biomarker and ganaxolone as a treatment in PCDH19-RE patients. The Company believes the increased patient enrollment has the potential to strengthen the ability to detect a meaningful signal as proof-of-concept for the allopregnanolone sulfate biomarker hypothesis. Marinus remains on-track to report topline data from this POC trial in the first half of 2021.

ShowHide Related Items >><<
MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

04/09/20 Craig-Hallum
Marinus Pharmaceuticals initiated with a Buy at Craig-Hallum
01/10/20 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $6 from $5 at H.C. Wainwright
12/20/19
Fly Intel: Top five analyst initiations
12/19/19 Oppenheimer
Marinus Pharmaceuticals initiated with an Outperform at Oppenheimer
MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

  • 29
    May
  • 11
    Dec
Hot Stocks
Marinus Pharmaceuticals says first patient enrolled in Phase 2 TSC trial » 07:14
06/30/20
06/30
07:14
06/30/20
07:14
MRNS

Marinus Pharmaceuticals

$2.52 /

-0.08 (-3.08%)

The first patient has…

The first patient has been enrolled in the Company's Phase 2 open-label trial to evaluate the safety and tolerability of adjunctive ganaxolone treatment in patients with TSC. The trial is expected to enroll approximately 30 patients ages 2 to 65. Patients will undergo a four-week baseline period followed by a 12-week treatment period where they will receive up to 600 mg of ganaxolone three times a day. Patients who meet eligibility criteria may continue ganaxolone treatment during a 24-week extension to the trial. The primary endpoint for the trial is percent change in 28-day primary seizure frequency for the treatment period relative to baseline. The Company plans to analyze allopregnanolone sulfate levels as part of the trial efficacy analysis.

ShowHide Related Items >><<
MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

04/09/20 Craig-Hallum
Marinus Pharmaceuticals initiated with a Buy at Craig-Hallum
01/10/20 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $6 from $5 at H.C. Wainwright
12/20/19
Fly Intel: Top five analyst initiations
12/19/19 Oppenheimer
Marinus Pharmaceuticals initiated with an Outperform at Oppenheimer
MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

  • 29
    May
  • 11
    Dec
Hot Stocks
Marinus Pharmaceuticals expects CDD Phase 3 trial results in Q3 » 07:13
06/30/20
06/30
07:13
06/30/20
07:13
MRNS

Marinus Pharmaceuticals

$2.52 /

-0.08 (-3.08%)

Marinus remains on-track…

Marinus remains on-track to report top-line data from the pivotal Phase 3 Marigold Study, which is evaluating the use of oral ganaxolone in children and young adults with CDD. The global, double-blind, placebo-controlled, clinical trial has enrolled 101 patients between the ages of 2 and 21 with a confirmed disease-related CDKL5 gene variant. In advance of topline data, Marinus has begun preparations for an expanded access program in CDD that will allow the Company, on positive data, to offer ganaxolone to patients who were unable to participate in the Phase 3 study.

ShowHide Related Items >><<
MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

04/09/20 Craig-Hallum
Marinus Pharmaceuticals initiated with a Buy at Craig-Hallum
01/10/20 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $6 from $5 at H.C. Wainwright
12/20/19
Fly Intel: Top five analyst initiations
12/19/19 Oppenheimer
Marinus Pharmaceuticals initiated with an Outperform at Oppenheimer
MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

  • 29
    May
  • 11
    Dec
Hot Stocks
Marinus Pharmaceuticals on track to begin SE Phase 3 trial in Q3 » 07:12
06/30/20
06/30
07:12
06/30/20
07:12
MRNS

Marinus Pharmaceuticals

$2.52 /

-0.08 (-3.08%)

Marinus has finalized the…

Marinus has finalized the protocol for its planned Phase 3 pivotal clinical trial in SE following its End of Phase 2 Meeting held in March 2020 and based on the successful results from its completed Phase 2 trial. The Phase 3 study will be a randomized, double-blind, placebo-controlled trial in SE patients who have failed benzodiazepines and 2 or more intravenous anti-epileptic drugs. The trial will enroll 124 patients randomized to receive ganaxolone or placebo adjunctive to standard of care at approximately 80-100 U.S. sites. Patients will receive a 36-hour infusion followed by a 12-hour taper for a total 48-hour treatment period, which, for patients randomized to receive ganaxolone, targets a plasma concentration of greater or equal to 500ng/mL for 12-hours.The co-primary endpoints for the study are proportion of patients with SE cessation within 30 minutes of treatment initiation without medications for the acute treatment of SE and proportion of patients with no progression to IV anesthesia for 36 hours following treatment initiation. Trial initiation on-track for Q3 2020 with topline data expected first half of 2022

ShowHide Related Items >><<
MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

04/09/20 Craig-Hallum
Marinus Pharmaceuticals initiated with a Buy at Craig-Hallum
01/10/20 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $6 from $5 at H.C. Wainwright
12/20/19
Fly Intel: Top five analyst initiations
12/19/19 Oppenheimer
Marinus Pharmaceuticals initiated with an Outperform at Oppenheimer
MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

  • 29
    May
  • 11
    Dec
Hot Stocks
Marinus Pharmaceuticals provides pipeline update » 07:12
06/30/20
06/30
07:12
06/30/20
07:12
MRNS

Marinus Pharmaceuticals

$2.52 /

-0.08 (-3.08%)

Marinus Pharmaceutical…

Marinus Pharmaceutical provided a pipeline update in advance of it clinical and commercial overview webinar. "With a final protocol in place, we are on-track to begin our Phase 3 pivotal trial in status epilepticus next quarter," said Scott Braunstein, M.D., Chief Executive Officer of Marinus. "Our Phase 3 trial is designed to demonstrate both rapid onset of antiepileptic activity along with sustained status cessation, allowing physicians to focus their attention on the patients' underlying disease state and avoid the often devastating consequences of uncontrolled SE and anesthesia induced coma. Our oral ganaxolone program has focused on rare genetic epilepsies with a biology-driven scientific foundation underserved by current available treatment options. To that end, we have initiated a Phase 2 study in tuberous sclerosis complex-related epilepsy and are preparing for our Phase 3 data readout in CDD next quarter. We look forward to sharing further details on our clinical and commercial strategies during our pipeline update event today and are thrilled to have KOL engagement and insight as we discuss our programs."

ShowHide Related Items >><<
MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

04/09/20 Craig-Hallum
Marinus Pharmaceuticals initiated with a Buy at Craig-Hallum
01/10/20 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $6 from $5 at H.C. Wainwright
12/20/19
Fly Intel: Top five analyst initiations
12/19/19 Oppenheimer
Marinus Pharmaceuticals initiated with an Outperform at Oppenheimer
MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

  • 29
    May
  • 11
    Dec
Conference/Events
Marinus Pharmaceuticals to hold a pipeline update webinar » 04:55
06/30/20
06/30
04:55
06/30/20
04:55
MRNS

Marinus Pharmaceuticals

$2.52 /

-0.08 (-3.08%)

Pipeline Update Webinar…

Pipeline Update Webinar to provide a clinical update and commercial overview on the Company's pipeline programs in Status Epilepticus, CDKL5 Deficiency Disorder and Tuberous Sclerosis Complex will be held on June 30 at 8 am. Webcast Link

ShowHide Related Items >><<
MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

04/09/20 Craig-Hallum
Marinus Pharmaceuticals initiated with a Buy at Craig-Hallum
01/10/20 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $6 from $5 at H.C. Wainwright
12/20/19
Fly Intel: Top five analyst initiations
12/19/19 Oppenheimer
Marinus Pharmaceuticals initiated with an Outperform at Oppenheimer
MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

  • 29
    May
  • 11
    Dec
Monday
Conference/Events
Marinus Pharmaceuticals to hold a pipeline update webinar » 16:36
06/29/20
06/29
16:36
06/29/20
16:36
MRNS

Marinus Pharmaceuticals

$2.52 /

-0.08 (-3.08%)

Pipeline Update Webinar…

Pipeline Update Webinar to provide a clinical update and commercial overview on the Company's pipeline programs in Status Epilepticus, CDKL5 Deficiency Disorder and Tuberous Sclerosis Complex will be held on June 30 at 8 am. Webcast Link

ShowHide Related Items >><<
MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

04/09/20 Craig-Hallum
Marinus Pharmaceuticals initiated with a Buy at Craig-Hallum
01/10/20 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $6 from $5 at H.C. Wainwright
12/20/19
Fly Intel: Top five analyst initiations
12/19/19 Oppenheimer
Marinus Pharmaceuticals initiated with an Outperform at Oppenheimer
MRNS Marinus Pharmaceuticals
$2.52 /

-0.08 (-3.08%)

  • 29
    May
  • 11
    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.